Tatva Chintan Pharma Chem Limited — Q1FY27 earnings call summary

Filed 21 July 2026 · Official transcript

Board approved 200cr INR greenfield capex for multiproduct facility; revenue target 300cr INR at peak
Q1 FY27 revenue 1,671mn INR +43% y-y, EBITDA 323mn INR +86% y-y
FY27 revenue growth guidance 25-30%; EBITDA margin guidance 20-22%
Semiconductor product qualified; commercial scale batch delivered; large opportunity expected
Semiconductor commercialization expected post Q4 FY28; patience required for scale-up
Structure Directing Agents demand strong; Euro 7 implementation driving growth
Electrolyte Salts revenue impacted by raw material shortages; hybrid battery commercialization progressing
Phase Transfer Catalysts revenue 428mn INR +38% q-q; growth driven by wider industry adoption